| 标题： | 临床试验加载药物经济学评价中国专家共识 |
| title： | Expert consensus on economic evaluations alongside clinical trials in China |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 管理 |
| field： | Administration |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 在中国设计和实施临床试验及临床试验加载药物经济学评价的研究人员以及卫生健康与医保管理等相关部门的决策制定者 |
| Guide users： | Researchers who design and conduct clinical trials and pharmacoeconomic evaluations of clinical trials in China, and decision makers in relevant departments of health care and health insurance management. |
| 证据分级方法： | 由于本共识不是基于系统评价的循证指南，故不作证据质量与推荐强度分级。 |
| Evidence grading method： | Because this consensus is not an evidence-based guideline based on systematic evaluation, it does not grade the quality of evidence and strength of recommendation. |
| 制定单位： | 中国药学会药物经济学专业委员会 |
| Formulating unit： | Professional Committee of Pharmacoeconomics of Chinese Pharmaceutical Association |
| 注册时间： | 2024-04-12 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN528 |
| Registration number： | |
| 指南制订的目的： | 旨在从中国医疗卫生体系与决策环境出发，围绕如何在临床试验中加载药物经济学评价这一主题，为中国学者和医药行业制定一份共识性的指导文件。 |
| Purpose of the guideline： | It aims to develop a consensus guidance document for Chinese scholars and the pharmaceutical industry around the theme of how to load pharmacoeconomic evaluation in clinical trials from the perspective of China's healthcare system and decision-making environment. |
最新注册
